Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Hong Kong · Delayed Price · Currency is HKD 21.72
-0.16 (-0.73%)
Apr 17, 2026, 3:30 PM HKT
HKG:6826 Revenue
In the year 2025, Shanghai Haohai Biological Technology had annual revenue of 2.45B CNY, down -8.71%. Shanghai Haohai Biological Technology had revenue of 547.22M in the quarter ending December 31, 2025, a decrease of -9.53%.
Revenue
2.45B CNY
Revenue Growth
-8.71%
P/S Ratio
3.43
Revenue / Employee
1.13M CNY
Employees
2,156
Market Cap
9.34B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45B | -233.36M | -8.71% |
| Dec 31, 2024 | 2.68B | 44.76M | 1.70% |
| Dec 31, 2023 | 2.63B | 531.47M | 25.27% |
| Dec 31, 2022 | 2.10B | 353.32M | 20.19% |
| Dec 31, 2021 | 1.75B | 425.69M | 32.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Ocumension Therapeutics | 895.09M |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |